课题基金 / 基金详情

NEUROPATHY ASSOCIATED WITH IMPAIRED GLUCOSE TOLERANCE

NEUROPATHY ASSOCIATED WITH IMPAIRED GLUCOSE TOLERANCE
与葡萄糖耐量受损相关的神经病
批准号:
7376473
负责人:
John Robinson Singleton
金额:
$5.27万
依托单位:
依托单位国家:
美国
项目类别:
财政年份:
2006
资助国家:
美国
项目状态:
已结题
起止时间:
2006-04-01 至 2007-02-28

项目摘要

项目成果

John Robinson Singleton的其他基金

相似基金

相关文献

中文摘要
翻译
点击翻译按钮获取中文摘要
英文摘要
This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. The subproject and investigator (PI) may have received primary funding from another NIH source, and thus could be represented in other CRISP entries. The institution listed is for the Center, which is not necessarily the institution for the investigator. Sensory neuropathy, often with pain, is a common neurologic problem. In developed countries, type 2 diabetes is the most frequent defined cause of sensory neuropathy. In approximately 40% of patients with neuropathy, no cause can be defined (?idiopathic neuropathy?). We and others have shown that 35-50% of patients with otherwise idiopathic neuropathy have impaired glucose tolerance (IGT), compared to 14% of the age matched general population. IGT is defined as a glucose level after a 2 hour oral glucose tolerance test (OGTT) between 140 and 200 mg/dL and a fasting plasma glucose less than 126 mg/dL. Patients with IGT almost uniformly have a painful sensory neuropathy, linking them to the phenotype of early diabetic neuropathy. The Diabetes Control and Complications Trial (DCCT) clearly showed that neuropathy onset and severity correlates with glycemic control in type I diabetes. In the DCCT, aggressive treatment of hyperglycemia prevented or slowed the progression of neuropathy, while the Diabetes Prevention Program (DPP) shows that intensive diet and exercise modification can prevent progression from IGT to diabetes and sets a standard of care for IGT patients. We hypothesize that episodic hyperglycemia contributes to a neuropathy that is clinically indistinguishable from that observed in patients with frank diabetes, and that aggressive treatment to normalize blood glucose levels will be necessary to slow progression of neuropathy in these patients. To test this hypothesis, we propose a prospective controlled trial to determine if treatment with intensive diet and exercise counseling can stabilize or reverse neuropathy in IGT patients
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
The Utah Regional Network for Excellence in Neuroscience Clinical Trials
  • 批准号:
    10208979
  • 项目类别:
  • 资助金额:
    $30.5万
  • 财政年份:
    2018
  • 负责人:
    John Robinson Singleton
  • 依托单位:
The Utah Regional Network for Excellence in Neuroscience Clinical Trials
  • 批准号:
    10593643
  • 项目类别:
  • 资助金额:
    $30.5万
  • 财政年份:
    2018
  • 负责人:
    John Robinson Singleton
  • 依托单位:
Developing Corneal Confocal Microscopy as a Screening Tool and Biomarker for Diabetic Neuropathy
  • 批准号:
    8832135
  • 项目类别:
  • 资助金额:
    $144.21万
  • 财政年份:
    2014
  • 负责人:
    John Robinson Singleton
  • 依托单位:
The Utah Regional Network for Excellence in Neuroscience Clinical Trials
  • 批准号:
    9293398
  • 项目类别:
  • 资助金额:
    $29.8万
  • 财政年份:
    2011
  • 负责人:
    John Robinson Singleton
  • 依托单位:
海外基金